Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;46(6):2833-2838.
doi: 10.1007/s00261-020-02877-w. Epub 2021 Jan 2.

Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer

Yonghua Bi #  1 , Xiaonan Shi #  2 , Jianzhuang Ren  1 , Mengfei Yi  1 , Xinwei Han  3 , Min Song  4
Affiliations

Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer

Yonghua Bi et al. Abdom Radiol (NY). 2021 Jun.

Abstract

Purpose: We aimed to assess the safety and efficacy of transarterial chemoembolization (TACE) with doxorubicin-loaded CalliSpheres® beads (DEB-TACE) for the treatment of patients with inoperable or recurrent colorectal cancer (CRC).

Methods: This retrospective study recruited 12 consecutive patients with histology confirmation of CRC who received DEB-TACE between August 2017 and April 2020. There were 9 male and 3 female, with a mean age 62.5 ± 14.9 (range 29-84). Patients' characteristics, medical imaging data, complications and DEB-TACE procedure were retrospectively reviewed. The disease control rate was defined as the sum of complete response, partial response and stable disease.

Results: DEB-TACE was successfully performed in all patients. All patients showed local disease control 1 month after DEB-TACE. Disease control rates were 90.9% and 70.0% at 3 and 6 months after DEB-TACE procedure, respectively. Disease-free interval was 11.0 to 81.8 months. Five patients (41.7%) received prior chemotherapy treatments. No severe complications or procedure-related deaths were observed. The median overall survival was 15.9 months, and median progression-free survival was 13.4 months.

Conclusion: DEB-TACE is a safe and effective treatment and could be a option for patients with inoperable or recurred CRC.

Keywords: CalliSpheres® beads; Colorectal cancer (CRC); Doxorubicin; Drug-eluting beads; Transarterial chemoembolization (TACE).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Benson AB, 3rd, Venook AP, Cederquist L, et al. (2017) Colon cancer, version 1.2017, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN 15(3):370-398.
    1. Van Cutsem E, Cervantes A, Adam R, et al. (2016) Esmo consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 27(8):1386-1422. - DOI
    1. Benson AB, Venook AP, Al-Hawary MM, et al. (2018) Nccn guidelines insights: Colon cancer, version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN 16(4):359-369.
    1. Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y (2019) Callispheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional tace in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat 181533033819830751.
    1. Zhou GH, Han J, Sun JH, et al. (2018) Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by callispheres(r) beads in chinese hepatocellular carcinoma patients. BMC Cancer 18(1):644. - DOI

LinkOut - more resources